Wildcat Capital Management’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,297,959
| Closed | -$1.07M | – | 8 |
|
|
2025
Q1 | $1.07M | Hold |
1,297,959
| – | – | 0.57% | 7 |
|
|
2024
Q4 | $1.23M | Hold |
1,297,959
| – | – | 0.49% | 5 |
|
|
2024
Q3 | $1.3M | Hold |
1,297,959
| – | – | 0.63% | 6 |
|
|
2024
Q2 | $1.61M | Hold |
1,297,959
| – | – | 0.39% | 14 |
|
|
2024
Q1 | $1.69M | Hold |
1,297,959
| – | – | 0.61% | 14 |
|
|
2023
Q4 | $1.62M | Hold |
1,297,959
| – | – | 0.56% | 15 |
|
|
2023
Q3 | $1.69M | Hold |
1,297,959
| – | – | 0.68% | 14 |
|
|
2023
Q2 | $2.23M | Hold |
1,297,959
| – | – | 0.85% | 15 |
|
|
2023
Q1 | $1.9M | Sell |
1,297,959
-140,273
| -10% | -$269K | 0.7% | 16 |
|
|
2022
Q4 | $2.33M | Hold |
1,438,232
| – | – | 0.89% | 17 |
|
|
2022
Q3 | $4.82M | Hold |
1,438,232
| – | – | 1.85% | 15 |
|
|
2022
Q2 | $5.24M | Hold |
1,438,232
| – | – | 1.73% | 15 |
|
|
2022
Q1 | $10.4M | Hold |
1,438,232
| – | – | 2.66% | 15 |
|
|
2021
Q4 | $19.5M | Hold |
1,438,232
| – | – | 3.18% | 12 |
|
|
2021
Q3 | $30.1M | Hold |
1,438,232
| – | – | 3.9% | 9 |
|
|
2021
Q2 | $34.4M | Hold |
1,438,232
| – | – | 3.91% | 6 |
|
|
2021
Q1 | $42.1M | Hold |
1,438,232
| – | – | 5.14% | 4 |
|
|
2020
Q4 | $43M | Buy |
+1,438,232
| New | +$45.1M | 5.4% | 3 |
|
Wildcat Capital Management's KRON Position: Q2 2025 in Review
Wildcat Capital Management sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 1,297,959 shares — an estimated $1.07M sold.
Wildcat Capital Management first reported a position in KRON in Q4 2020 and held it in 18 quarters. The position peaked at $43M in Q4 2020. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Wildcat Capital Management reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Wildcat Capital Management sold 1,297,959 Kronos Bio shares in Q2 2025, an estimated $1.07M.
- Wildcat Capital Management first reported a position in Kronos Bio in Q4 2020 and held it in 18 quarters.
- Wildcat Capital Management's Kronos Bio position peaked at $43M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Wildcat Capital Management's 13F filing for Q2 2025, filed 18 Jul 2025.